Neogen (NEOG) Valuation in Focus After New CFO Appointment and Leadership Shuffle

Neogen (NEOG) has named Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025. Riggsbee’s arrival brings over two decades of strategic finance experience in diagnostics and healthcare, which could factor into investor perspectives on the stock.

See our latest analysis for Neogen.

Neogen’s stock has shown tentative signs of momentum lately, posting a strong 90-day share price return of 28.8% even as its year-to-date decline remains steep. Recent executive appointments, including a new CFO and a refreshed board, have arrived in the context of a five-year total shareholder return of -83.2%, highlighting how the company is working to regain investor confidence after a challenging run.

If management changes in healthcare spark your curiosity, you might also enjoy discovering See the full list for free.

With fresh leadership and a recent rebound in share price, the question for investors is whether Neogen is still undervalued at current levels or if the market is already factoring in the company’s prospects for recovery and growth.

Most Popular Narrative: 26.5% Undervalued

With Neogen’s most popular narrative assigning a fair value nearly 27% above the latest close, there is a sizable gap between analyst expectations and the market’s current pricing. The underlying logic, driven by future profit assumptions and margin improvements, sets up a clear tension for anyone considering the stock’s rebound.

Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.

Read the complete narrative.

Earnings upgrades, a margin transformation, and Big Food Safety tailwinds power this valuation. Want to uncover the rare combination of forecasts and profit levers at work? See what numbers drive the latest fair value math? This future-focused narrative is not what you might expect for an unprofitable business today.

Result: Fair Value of $8.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent integration issues with the 3M Food Safety acquisition and ongoing weakness in animal safety revenues may still undermine this bullish outlook.

Find out about the key risks to this Neogen narrative.

Build Your Own Neogen Narrative

If you have your own take on Neogen’s numbers or want to back your own perspective with data, you can build a narrative in just a few minutes. Do it your way

A great starting point for your Neogen research is our analysis highlighting 1 important warning sign that could impact your investment decision.

Looking for More Investment Opportunities?

Don’t let the next big winner pass you by. Use the Simply Wall St Screener to spot companies positioned for breakthroughs, income, or rapid growth.

• Unlock untapped sources of monthly income by checking out these 24 dividend stocks with yields > 3% offering consistent yields and robust payout histories.
• Ride the momentum of artificial intelligence by following these 26 AI penny stocks making real-world impacts through next-generation technologies.
• Capitalize on overlooked value by getting ahead with these 831 undervalued stocks based on cash flows handpicked using cash flow fundamentals before the market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com